Safinamide is the first new molecule in 20 years to be used in the treatment of Parkinson’s.
Zambon s.p.A. entrusted Catalent as its partner for timely development and launch of Safinamide under the brand name Xadago® to a worldwide target market.
Thank you for submitting the form. Your enquiry will be submitted to the company.
Please check your email to download the Product.
Safinamide is the first new molecule in 20 years to be used in the treatment of Parkinson’s.
Zambon s.p.A. entrusted Catalent as its partner for timely development and launch of Safinamide under the brand name Xadago® to a worldwide target market.